Medical treatment of epilepsy

Expert Opinion on Emerging Drugs

Volumn 8, Issue 2, 2003, Pages 457-467

  Bauer, Jürgen ^a   Reuber, Markus ^b  

^a UNIVERSITY OF BONN   (Germany)

^b SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Antiepileptic drugs; Epilepsy; Seizure

Indexed keywords

1 (4 CHLOROPHENYL) 4 MORPHOLINO 3 IMIDAZOLIN 2 ONE; ANTICONVULSIVE AGENT; CARABERSAT; CARBAMAZEPINE; CONANTOKIN G; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; FOSPHENYTOIN SODIUM; GABAPENTIN; GANAXOLONE; HARKOSERIDE; LAMOTRIGINE; LOSIGAMONE; OXCARBAZEPINE; PHENYTOIN; PREGABALIN; REMACEMIDE; RETIGABINE; RUFINAMIDE; SAFINAMIDE; SORETOLIDE; TALAMPANEL; TIAGABINE; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VALROCEMIDE; VIGABATRIN; ZONISAMIDE;

ALLERGIC REACTION; ATAXIA; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DIZZINESS; DOSE RESPONSE; DRUG CLEARANCE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; ENDOCRINE DISEASE; EPILEPSY; EPILEPTIC STATE; EVIDENCE BASED MEDICINE; FATIGUE; FOCAL EPILEPSY; GASTROINTESTINAL SYMPTOM; GENERALIZED EPILEPSY; GRAND MAL SEIZURE; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; OVARY POLYCYSTIC DISEASE; PARESTHESIA; PRURITUS; RASH; REVIEW; SIDE EFFECT; TERATOGENICITY; TREATMENT OUTCOME; WEIGHT GAIN;

ANTICONVULSANTS; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; EPILEPSY, GENERALIZED; HUMANS; PRACTICE GUIDELINES;

EID: 0346996942     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.8.2.457     Document Type: Review

References (53)

1. WALKER MC, SANDER JW: New antiepileptic drugs. Expert Opin. Investig. Drugs (1999) 8:1497-1510.
2. WILLMORE LJ: Clinical pharmacology of new antiepileptic drugs. Neurology (2000) 55(Suppl.):S17-S24.
3. KWAN P, BRODIE MJ: Early identification of refractory epilepsy. N. Engl. J. Med. (2000) 342:314-319. Important study describing the effectiveness of monotherapy.
4. FRENCH JA, SCHACHTER S: A workshop of antiepileptic drug monotherapy indications. Epilepsia (2002) 43(Suppl. 10):3-27.
5. DUVAL X, CHOSIDOW O, SEMAH F, LIPSKER D, FRANCES C, HERSON S: Lamotrigine versus carbamazepine in epilepsy. Lancet (1995) 345:1301-1302.
6. BRODIE MJ: Monostars: an aid to choosing an antiepileptic drug as monotherapy. Epilepsia (1999) 40(Suppl. 6):S17-S22.
7. KWAN P, BRODIE MJ: Epilepsy after the first drug fails: substitution or add-on? Seizure (2000b) 9:464-468. Helpful analysis with discussion of the respective advantages of mono- or combination therapy.
8. DECKERS CL, CZUCZWAR SJ, HEKSTER YA: Selection of anticonvulsant drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia (2000) 41:1364-1374.
9. MARSON AG, KADIR ZA, HUTTON JL, CHADWICK D: The antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia (1997) 38:859-880. Analysis of the relative anticonvulsant potency of different new AEDs.
10. MARSON AG, HUTTON JL, LEACH JP et al.: Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review. Epilepsy Res. (2001) 46:259-270. Informal expert review of the role of new AEDs.
11. ELFERINK JA, VAN ZWIETEN-BOOT BJ: New antiepileptic drugs. Analysis based on number needed to treat shows differences between drugs studied. Br. Med. J. (1997) 314:603. Analysis of the relative anticonvulsant potency of different new AEDs.
12. CHAISEWIKUL R, PRIVITERA MD, HUTTON JL, MARSON AG: Levetiracetam add-on for drug-resistant localization related (partial) epilepsy. Cochrane Database Syst. Rev. (2001) 1:CD001901.
13. KARCESKI S, MORRELL M, CARPENTER D: The expert consensus guideline series. Treatment of epilepsy. Epilepsy Behav. (2001) 2:A1-A50. Up-to-date statement of expert opinion on the use of AEDs in different clinical scenarios. Tables 2, 4, 5, 6 & 7 reprinted from this article, © 2001, with permission from Elsevier.
14. SCHMIDT D, ARROYO S, BAULAC M et al.; Recommendations on the clinical use of oxcarbazepine in the treatment of epilepsy: a consensus view. Acta Neurol. Scand. (2001) 104:167-170.
15. KWAN P, BRODIE MJ: Neuropsychological effects of epilepsy and antiepileptic drugs. Lancet (2001) 357:216-222. Concise review of neuropsychological effects of AEDs.
16. BAUER J, ISOJÄRVI JIT, HERZOG AG et al.: Reproductive dysfunction in women with epilepsy: Recommendations for evaluation and management. J. Neurol. Neurosurg. Psychiatry (2002) 73:121-125. Current consensus on diagnosis and management of endocrine disturbances caused by AEDs.
17. STOFFEL-WAGNER B, BAUER J, FLÜGEL D, BRENNEMANN W, KLINGMÜLLER D, ELGER CE: Serum sex hormones are altered in patients with chronic temporal lobe epilepsy receiving anticonvulsant medication. Epilepsia (1998) 39:1164-1173.
18. BARRETT C, RICHENS A: Epilepsy and pregnancy: report of an epilepsy research foundation workshop. Epilepsy Res. (2003) 52:147-187.
19. HOLMES LB, HARVEY EA, COULL BA et al.: The teratogenicity of anticonvulsant drugs. N. Engl. J. Med. (2001) 344:1132-1138.
20. KAUR S, SARKAR R, THAMI GP, KANWAR AJ: Anticonvulsant hypersensitivity syndrome. Pediatr. Dermatol. (2002) 19:142-145.
21. BIALER M, JOHANNESSEN SI, KUPFERBERG HJ, LEVY RH, LOISEAU P, PERUCCA E: Progress report on new antiepileptic drugs: a summary of the Fourth Eilat Conference (EILAT IV): Epilepsy Res. (1999) 34:1-41. Detailed expert analysis of AEDs in development.
22. BIALER M, JOHANNESSEN SI, KUPFERBERG HJ, LEVY RH, LOISEAU P, PERUCCA E: Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V): Epilepsy Res. (2001) 43:11-58. Detailed expert analysis of AEDs in development.
23. BIALER M, JOHANNESSEN SI, KUPFERBERG HJ, LEVY RH, LOISEAU P, PERUCCA E: Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI): Epilepsy Res. (2002) 51:31-71. Detailed expert analysis of AEDs in development.
24. RUNDFELDT C, SIGEL E, EGERLAND U: First insights in the mode of action of AWD 131-138: allosteric modulation of GABA-induced currents. Naunyn Schmiedeberg's Arch. Pharmacol. (1998) 357(Suppl. 4):98.
25. DONEVAN SD, MCCABE RT: Conantokin G is an NR2B selective competitive antagonist of NMDA receptors. Mol. Pharmacol. (2000) 58:614-623.
26. WITTEKINDT B, MALANY S, SCHEMM R et al.: Point mutations identify the glutamate binding pocket of the N-methyl-D-aspartate receptor as major site of conantokin-G inhibition. Neuropharmacology (2001) 41:753-761.
27. PROROK M, CASTELLINO FJ: Structure-function relationships of the NMDA receptor antagonist conantokin peptides. Curr. Drug Targets (2001) 2:313-322.
28. BAZAN NG, BIRKLE DL, TANG W, REDDY TS: The accumulation of free arachnoic acid, diacylglycerols, prostaglandins, and lipoxygenase reaction products in the brain during experimental epilepsy. Adv. Neurol. (1986) 44:879-902.
29. MONAGHAN EP, MCAULEY JW, DATA JL: Ganaxolone: a novel positive allosteric modulator of the GABA(A) receptor complex for the treatment of epilepsy. Expert Opin. Investig. Drugs (1999) 8:1663-1671.
30. LAXER K, BLUM D, ABOU-KHALIL BW, MORRELL MJ, LEE DA, MONAGHAN EP: Assessment of ganaxolone's anticonvulsant activity using a randomized, double-blind, presurgical trial design. Epilepsia (2000) 41:1187-1194.
31. GEBHARDT C, BREUSTEDT JM, NOLDNER M, CHATTERJEE SS, HEINEMANN U: The antiepileptic drug losigamone decreases the persistent Na+ current in rat hippocampal neurons. Brain Res. (2001) 920:27-31.
32. ELGER CE, STEFAN H, RUNGE U, DIENEL A: Losigamone; double-blind study of 1,500 mg/day versus placebo in patients with focal epilepsy. Losigamone Study Group. Epilepsia (1996) 37(Suppl. 4):64.
33. BAUER J, DIENEL A, ELGER CE: Losigamone add-on therapy in partial epilepsy: a placebo-controlled study. Acta Neurol. Scand. (2001) 103:226-230.
34. FRENCH J, MALICSI MJR, KUGLER AR, KNAPP LE, BOCKBRADER HN, GARAFALO EA: Pregabalin adjunctive therapy in patients with partial seizures. Epilepsia (1999) 40(Suppl. 7):106.
35. ROBBINS JL, KUGLER AR, ANHUT H, SMITH TM, GARAFALO EA: Pregabalin shows anticonvulsant activity onset by second day. Epilepsia (2001) 42(Suppl. 7):211.
36. RAMSAY RE, KUGLER AR, ANHUT H et al: Pregabalin adjunctive therapy in patients with partial seizures. Epilepsia (2001) 42(Suppl. 7):211.
37. LEACH JP, MARSON AG, HUTTON JL: Remacemide for drug-resistant localization related epilepsy (Cochrane Review). Cochrane Database Syst. Rev. (2002) 4:CD001900.
38. LEACH JP, GIRVAN J, JAMIESON V, JONES T, RICHENS A, BRODIE MJ: Mutual interaction between remacemide hydrochloride and phenytoin. Epilepsy Res. (1997) 26:381-388.
39. JONES MW, BLUME W, GUBERINAN A et al.: Remacemide hydrochloride (300 mg, 600 mg, 800 mg/day) efficacy and safety versus placebo in patients with refractory epilepsy. Epilepsia (1996) 37(Suppl. 5):166.
40. CHADWICK DW, BETTS TA, BODDIE HG et al.: Remacemide hydrochloride as an add-on therapy in epilepsy: a randomized, placebo-controlled trial of three dose levels (300, 600 and 1200 mg/day) in a Q.I.D. regimen. Seizure (2002) 11:114-123.
41. DEVINSKY O, VAZQUEZ B, FAUGHT E et al.: A double-blind, placebo-controlled study of remacemide hydrochloride in patients with refractory epilepsy following presurgical assessment. Seizure (2002) 11:371-376.
42. RUNDFELDT C, NETZER R: Investigations into the mechanism of action of the new anticonvulsant retigabine. Interaction with GABAergic and glutaminergic neurotransmission and with voltage gated ion channels. Arzneimittelforschung (2000) 50:1063-1070.
43. PALHAGEN S, CANGER R, HENRIKSEN O, VAN PARYS JA, RIVIERE ME, KAROLCHYK MA: Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy. Epilepsy Res. (2001) 43:115-124.
44. CHAZOT PL: Safinamide (Newron Pharmaceuticals). Curr. Opin. Investig. Drugs (2001) 2:809-813.
45. HORVATH K: Highlights of CNS research at IDR: 2,3-benzodiazepines. Pharmazie (2001) 56(Suppl. 1):S56-S61.
46. CHAPPELL AS, SANDER JW, BRODIE MJ et al.: A crossover, add-on trial of talampanel in patients with refractory partial seizures. Neurology (2002) 58:1680-1682.
47. LANGAN YM, LUCAS R, JEWELL H et al.: Talampanel, a new antiepileptic drug: single- and multi-dose pharmacokinetics and initial 1-week experience in patients with chronic intractable epilepsy. Epilepsia (2003) 44:46-53.
48. ISOHERRANEN N, WOODHEAD JH, WHITE HS, BIALER M: Anticonvulsant profile of valrocemide (TV1901): a new antiepileptic drug. Epilepsia (2001) 42:831-836.
49. KNAPP LE, KUGLER AR, ELDON MA: Fosphenytoin: pharmacokinetics and administration. Emerg. Med. (1996) 28(Suppl. 4):9-16.
50. FISCHER JH, ALLEN FH, RUNGE J et al: Fosphenytoin (Cerebryx) in status epilepticus: safety, tolerance, and pharmacokinetics. Epilepsia (1996) 37(Suppl. 5):202.
51. RAMSAY RE, DETOLEDO J; Intravenous administration of fosphenytoin: options for the management of seizures. Neurology (1996) 46(Suppl. 1):S17-S19.
52. DEVINSKY O, LEPPIK H, WILLMORE LJ et al.: Safety of intravenous valproate. Ann. Neurol. (1995) 38:670-674.
53. http://www.liv.ac.uk/neuroscience/sanad Study of Standard and New Antiepileptic Drugs.